Residual IDH1-Mutant Tumor Cell Quantification Study

NANot yet recruitingINTERVENTIONAL

Enrollment

105

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

December 31, 2030

Study Completion Date

December 31, 2030

Conditions

Glioma

Interventions

DEVICE

UR-ddPCR

The investigational UR-ddPCR assay will be performed on collected tissue specimens during the participant's scheduled surgical visit.

Trial Locations (1)

NYU Langone Health, New York

All Listed Sponsors

lead

NYU Langone Health

OTHER

NCT07219199 - Residual IDH1-Mutant Tumor Cell Quantification Study | Biotech Hunter | Biotech Hunter